{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005329","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.473541+00:00","generated_at":"2026-06-18T19:40:41.985743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amarin Q4 2022 net income $0.9M; revenue down 38% YoY; positive free cash flow $4M","bullets":["Q4 2022 net product revenue $89.5M, down 38% YoY; U.S. revenue stabilized at $88.0M vs $87.9M in Q3.","GAAP net income $0.9M ($0.00 EPS); non-GAAP adjusted net income $7.3M ($0.02 EPS).","Positive free cash flow of $4M in Q4; cost savings program on track to exceed $100M target.","European expansion: VAZKEPA launched in 5 markets, pricing negotiations in 5 more; peak revenue potential $1B+ in Europe.","International: 6 regulatory approvals in 2022, plus New Zealand in Jan 2023; license agreement with CSL Seqirus for Australia/NZ."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005329","json":"https://secwatch.observer/filing/0000950170-23-005329.json","markdown":"https://secwatch.observer/filing/0000950170-23-005329.md","text":"https://secwatch.observer/filing/0000950170-23-005329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017023005329/0000950170-23-005329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017023005329/amrn-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T19:40:41.985743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"839b75194efa99cfd3391045d5243033b62811d9","claim":"AMARIN CORP PLCUK reported the three months ended December 31, 2022 results: revenue $90.2 million, net income $0.9 million, EPS $0.00 per share.","evidence_excerpt":"Financial Update Total net revenue for the three months ended December 31, 2022 was $90.2 million, compared to $144.5 million in the corresponding period of 2021, a decrease of 38%. Net product revenue for the three months ended December 31, 2022 was $89.5 million, compared to $143.7 million in the corresponding period of 2021, a decrease of 38%. This decrease was driven primarily by a decrease in volume of VASCEPA sales to Amarin’s customers in the United States, which were adversely impacted by generic availability in the United States. USA net product revenue was $88.0 million for Q4 2022 compared to $87.9 million in Q3 2022. Amarin recognized licensing and royalty revenue of approximately $0.7 million and $0.8 million during the three months ended December 31, 2022 and 2021, respectively, from VASCEPA-related commercial sales from our partners in Canada, the China region and the Middle East. Cost of goods sold for the three months ended December 31, 2022 was $26.6 million, compared","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017023005329/0000950170-23-005329-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$90.2 million"},{"label":"Net income","value":"$0.9 million"},{"label":"EPS","value":"$0.00 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}